Oliver Gassmann Book order

Transformation through digital innovation is becoming an imperative for every city. The ‘Smart City’ concept promises to solve the most urgent queries of progressive urbanization in the area of mobility, energy, water supply, security, housing deprivation, and inclusion. Despite the exploitation of existing potential in lighthouse-cities that include Barcelona, London, Munich, Lyon, and Vienna, the less tenacious pursuit of smart city possibilities in the majority of municipalities has resulted in major discrepancies between leading smart cities and those that are less aspirational. Although the necessity of action is frequently recognized, an appropriate path of action remains obscure. Smart Introducing Digital Innovation to Cities offers answers, with clarifying examples, to questions that have remained unanswered for many cities. The book identifies and addresses the core elements and potential of smart cities, best practice methods and tools to be implemented, as well as how diverse stakeholders might be effectively integrated. Based on perennial international research in the field of smart cities, this book brings together the authors' collective experience in practice-based political, administrative, and economic projects to provide a common framework to guide and engage key stakeholders in the transformation and realization of smart cities.

The book offers an extensive literature review of Business Model Innovation (BMI), examining 50 management theories to provide fresh insights into this emerging field. It highlights that research on BMI is still developing, revealing its significance beyond being merely a subset of strategy or innovation studies. This analysis aims to deepen understanding of BMI and its implications for management practices.

A strong business model is the bedrock to business success. But all too often we fail to adapt, clinging to outdated models that are no longer delivering the results we need. The brains behind The Business Model Navigator have discovered that just 55 business models are responsible for 90% of the world's most successful businesses. These 55 models – from the Add-On model used by Ryanair to the Subscription model used by Spotify – provide the blueprints you need to revolutionise your business and drive powerful change. As well as providing a practical framework for adapting and innovating your business model, this book also includes each of the 55 models in a quick-read format that “An excellent toolkit for developing your business model . ” Dr Heinz Derenbach, CEO, Bosch Software Innovations

China is dramatically catching up and is rapidly becoming a leading technological innovator on the global scale. The number of Chinese firms with global ambitions is growing fast, more and more technological innovation is coming from China, and the number of patents in China is also growing steadily. The negative side of this development is the still insufficient protection of intellectual property in China. The phenomenon of counterfeits originating from China has increased constantly over the past two decades. Moreover, within the past ten years the scale of intellectual property theft has risen exponentially in terms of its sophistication, volume, the range of goods, and the countries affected. This book addresses managers dealing with innovation in China, and offers concrete advice on how Western firms can benefit from these innovations. Among others, it provides examples and checklists to help decision-makers active in China.

Pharmaceutical giants have been doubling their investments in drug development, only to see new drug approvals to remain constant for the past decade. This book investigates and highlights a set of proactive strategies. The authors focus on three sources of pharmaceutical innovation: new management methods, new technologies, and new forms of internationalization. Their findings are illustrated in the case of the Swiss pharmaceutical industry, the leading exporter of pharmaceutical products in percentage of GDP, and some of its main pharmaceutical firms such as Novartis and Hoffmann-La Roche.